New Canada Drugs for Heart Failure

During the previous trials, treatments used in alleviating heart failure look more secure than the recent medications utilized.  In lieu, a new heart failure med may revolutionize the manner physicians cure this troublesome state.

800x600 Normal 0 false false false EN-PH X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Calibri","sans-serif"; mso-bidi-font-family:"Times New Roman";}

During the previous trials, treatments used in alleviating heart failure look more secure than the recent medications utilized.  In lieu, a new heart failure Canadian drug may revolutionize the manner physicians cure this troublesome state.  Heart failure, also known as congestive heart failure, happens if the heart is unable to pump strong enough in order for the blood to access the different parts of the body.

An experimental drug, omecamtiv mecarbil, which is being worked out by Cytokinetics Inc. in San Francisco may provide a substitute to present medications which will avoid patients to buy Accupril, based on the findings of two clinical trials released Aug. 20 in a special issue of The Lancet.

"It improves heart function in a completely new and unique manner," according to Dr. John R. Teerlink, a cardiologist at the San Francisco Veterans Affairs Medical Center and author of one of the recent studies.

"The drug directly increases the activation of certain heart muscle proteins, effectively recruiting 'more hands on the rope' with each heartbeat," he stated. "By improving the efficiency and performance of the heart, it is our hope that patients with heart failure will actually feel better with fewer symptoms of fatigue and shortness of breath, and perhaps even live longer," he added.

The presently available heart failure meds in various Canadian drugstore pharmacies, like milrinone (Primacor) and dobutamine (Dobutrex), indirectly boost heart performance, and can bring hazardous, even lethal, heart rhythm irregularities, Teerlink said. "These drugs are 'necessary evils' because they are the only currently available pharmacologic means to increase heart function," he conveyed.

"It is a promising drug, but we have been down this road before," he said.

"When you have heart failure, the pumping action of the heart is weak, so not enough blood gets to the body, and you feel short of breath, sleep a lot and your kidneys don't work," Dr. Ronald Zolty explained, director of the heart failure program at the Albert Einstein College of Medicine in New York City.

"Existing drugs do improve the squeeze, but they also increase mortality," he stated.

"The major problem we face in treating heart failure is how can we make the heart squeeze harder," Dr. Michele Hamilton said, director of the heart failure program at Cedars-Sinai Heart Institute in Los Angeles.  "To date, no medications have proven effective or safe, and as a result, doctors focus on getting rid of excess fluid buildup and reducing stress on the heart," she said.

"Medications that make the heart squeeze harder put more stress on the heart, and the patients die sooner. It is akin to whipping a tired horse as it goes uphill," she conveyed.

"It's great to see a new medication being tested and developed," Hamilton said. But, "we are far away from the finish line."

 

Article Tags: Heart Failure

Source: Free Articles from ArticlesFactory.com

ABOUT THE AUTHOR